Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Biotechnology

Healthcare
$3.77 -3.37%

-$0.34 today

Market cap
$186.36M
Beta
2.40
P/E (TTM)
-2.7
EPS (TTM)
-$3.53
52W Low $1.47High $14.53

Volume 0.97M

Average 0.48M

ARTV Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Artiva Biotherapeutics, Inc.NASDAQ: ARTV

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $666K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $666K.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $666K or moves back toward the trailing-twelve-month quarterly average of $166.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$666K— QoQ
Last fiscal yearDec 2025
$2.6M— YoY
LTMMar 2026
$666K— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
2.6M USD
Year-over-year change
—

Cost of Revenue vs competitors

How ARTV compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
ARTV Competitors
Cost of Revenue for ARTV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IFRXInflaRx N.V.LTM Mar 2026€7.26M EUR+133.7%—24746.3%
STTKShattuck Labs, Inc.LTM Mar 2026$1.82M USD-36.2%—182.0%
DTILPrecision BioSciences, Inc.LTM Mar 2026$1.37M USD——3.0%
STROSutro Biopharma, Inc.LTM Mar 2026$1.28M USD-28.6%-4.0%1.3%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$666K USD———
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$151K USD———
ALXOALX Oncology Holdings Inc.LTM Mar 2026$150K USD-31.8%——
CNTBConnect Biopharma Holdings LimitedFY2025$0 USD——0.0%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$0 USD-100.0%——
Peer median (excluding ARTV) —-31.8%-4.0%3.0%

Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2M4.93M33.49M251K0
Cost of Revenue00002.6M
Gross Profit2M4.93M33.49M251K(2.6M)
Gross Margin100.0%100.0%100.0%100.0%—
Research & Development42.41M43.98M50.25M50.33M69.54M
Selling, General & Admin12.86M20.78M13.91M17.21M20.27M
Operating Expenses55.27M64.76M64.16M67.53M88.01M
Depreciation & Amortization248K1.16M2.27M2.43M2.6M
EBITDA(71.58M)(57.18M)(25.36M)(56.06M)(81.27M)
EBITDA Margin-3575.3%-1159.5%-75.7%-22335.5%—
Operating Income(53.27M)(59.83M)(30.67M)(67.28M)(90.61M)
Operating Margin-2660.9%-1213.3%-91.6%-26805.6%—
Interest Income01.29M2.54M5.35M5.96M
Interest Expense00000
Other Income / Expenses(18.55M)1.49M3.05M8.79M6.75M
Income Before Tax(71.83M)(58.34M)(27.62M)(58.49M)(83.87M)
Pre-Tax Margin-3587.7%-1183.0%-82.5%-23304.0%—
Income Tax Expense053K72K00
Net Income(71.83M)(58.39M)(27.7M)(58.49M)(83.87M)
Net Margin-3587.7%-1184.1%-82.7%-23304.0%—
EPS (Basic)(4.08)(3.32)(1.19)(5.20)(3.43)
EPS (Diluted)(4.08)(3.32)(1.19)(5.20)(3.43)
Weighted Avg Shares17.58M17.58M23.28M24.36M24.44M
Weighted Avg Shares (Diluted)17.58M17.58M23.28M24.36M24.44M

Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Intrinsic Alpha fair value

Locked

Current Price

$3.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.